Michel Alexandre Yazbek

Michel Alexandre Yazbek

Auto-generated profile, based on publicly available information

Michel Alexandre Yazbek

Universidade Estadual de Campinas (Unicamp), São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
DLDhruvkumar Laheru
Dhruvkumar Laheru
AAAnna Antony
Anna Antony
SCSUELI CARNEIRO
SUELI CARNEIRO
Vito Di LerniaVito Di Lernia
Vito Di Lernia
AGAmit Garg
Amit Garg
MYMichel Alexandre Yazbek
Michel Alexandre Yazbek
Objective: Nail psoriasis is common, impairs fine motor finger functioning, affects cosmesis, and is associated with a lower quality of life. This review updates the previous Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for nail psoriasis.Methods: This systematic literature review of the PubMed, MEDLINE, Embase, and Cochrane databases examined the updated evidence since the last GRAPPA nail psoriasis treatment recommendations published in 2014. Recommendations are based on preformed PICO (Patient/Population - Intervention - Comparison/Comparator - Outcome) questions formulated by an international group of dermatologists, rheumatologists, and patient panel members. Data from this literature review were evaluated in line with Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology.Results: Overall, there is insufficient evidence to make any recommendation for the use of topical corticosteroids, topical calcipotriol, topical tazarotene, topical cyclosporine, dimethyl fumarates/fumaric acid esters, phototherapy, and alitretinoin. There is a low strength of evidence to support the use of calcipotriol and corticosteroid preparations, topical tacrolimus, oral cyclosporine, oral methotrexate, intralesional corticosteroids, pulsed dye laser, acitretin, Janus kinase inhibitors, and apremilast.Conclusion: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.

19 January 2021 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
RLRicardo da Cruz Lage
Ricardo da Cruz Lage
CMClaudia Diniz Lopes Marques
Claudia Diniz Lopes Marques
TOThauana Luiza Oliveira
Thauana Luiza Oliveira
GRGUSTAVO Gomes RESENDE
GUSTAVO Gomes RESENDE
CKCharles Lubianca Kohem
Charles Lubianca Kohem
MPMarcelo M Pinheiro
Marcelo M Pinheiro
Spondyloarthritis (SpA) is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. Over some decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been the basis for the pharmacological treatment of patients with axial spondyloarthritis (axSpA). However, the emergence of the immunobiologic agents brought up the discussion about the role of NSAIDs in the management of these patients. The objective of this guideline is to provide recommendations for the use of NSAIDs for the treatment of axSpA. A panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of randomized clinical trials for 15 predefined questions. The Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations were used, and at least 70% agreement of the voting panel was needed. Fourteen recommendations for the use of NSAIDs in the treatment of patients with axSpA were elaborated. The purpose of these recommendations is to support clinicians’ decision making, without taking out his/her autonomy when prescribing for an individual patient.

1 May 2012 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Open access
MYMichel A. Yazbek
Michel A. Yazbek
PVPaulo Velho
Paulo Velho
WNWilson Nadruz
Wilson Nadruz
NMNazira Mahayri
Nazira Mahayri
SASimone Appenzeller
Simone Appenzeller
LCLilian Tereza Lavras Costallat
Lilian Tereza Lavras Costallat
Low-molecular-weight heparin-induced skin necrosis can occur as a clinical feature of heparin-induced thrombocytopenia syndrome. Heparin-induced thrombocytopenia and antiphospholipid syndromes have some clinical features in common, including thrombocytopenia and thrombotic events. We describe a 46-year-old woman who developed extensive necrosis in the breast and other sites secondary to the use of enoxaparin after an elective hysterectomy. During the postoperative period, diagnoses of systemic lupus erythematosus and antiphospholipid syndrome were made because of some clinical and laboratory features (seizure, nephritis, bicytopenia, positive nuclear antibody, and positive antiphospholipid antibodies with a previous thrombotic event). The patient's clinical course improved only after corticosteroid therapy and the suspension of enoxaparin. Heparin-induced thrombocytopenia and antiphospholipid syndromes can have platelet factor 4 as a common denominator in their pathogenesis because platelet factor 4 tetramers can bind β2-glycoprotein molecules. This case suggests that use of low-molecular-weight heparins could be more risky in patients with an underlying immune disease and/or could trigger immune reactions that must be analyzed in larger studies.

12 February 2026 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
CMC. D. L. Marques
C. D. L. Marques
GRGUSTAVO Gomes RESENDE
GUSTAVO Gomes RESENDE
MPMarcelo M Pinheiro
Marcelo M Pinheiro
CSC. G. S. Saad
C. G. S. Saad
AMA. O. Marinho
A. O. Marinho
PSP. D. Sampaio-Barros
P. D. Sampaio-Barros
Background: Sex differences in axial spondyloarthritis (axSpA) are increasingly recognized, with women often reporting higher disease burden despite similar objective inflammatory markers. This study aimed to compare clinical features, disease activity, function, quality of life, and treatment patterns between men and women with axSpA and identify sex-specific predictors of disease outcomes using data from the Brazilian Registry of Spondyloarthritis (RBE). Methods: This was a cross-sectional, observational study based on data from the RBE, a nationwide multicenter cohort including 828 patients (568 men and 260 women) from 17 referral centers across Brazil. Standardized clinical and demographic data were collected using the REDCap platform. Disease activity (ASDAS-CRP, BASDAI), physical function (BASFI), spinal mobility (BASMI), and quality of life (ASQoL) were assessed with validated instruments. Sex-stratified multivariable linear regression models were constructed to identify independent predictors of each outcome. Results: Women presented higher disease activity (median BASDAI 4.5 vs. 3.2; ASDAS-CRP 2.2 vs. 1.9), greater functional limitation (BASFI 5.0 vs. 4.0), and poorer quality of life (ASQoL 9.0 vs. 7.0) compared to men, despite similar CRP levels. Psychological distress was more frequent in women, while men had worse spinal mobility (BASMI 4.0 vs. 3.5) and higher HLA-B27 positivity. Regression models revealed that shoulder and hip pain were relevant predictors of disease activity in both sexes, but psychological factors and work activity more strongly influenced outcomes in women. Men’s disease burden was more associated with structural damage and cardiometabolic comorbidities. Conclusions: This study highlights distinct sex-related clinical patterns in axSpA. Women reported higher symptom burden, functional limitations, and reduced quality of life, largely influenced by subjective symptoms and comorbidities. Conversely, men presented greater structural impairment and different comorbidity profiles. These findings support the need for sex-informed clinical assessments and individualized management strategies in axSpA to tailor the care of these sex-specific disease trajectories, which may enhance equity and outcomes in real-world settings.

1 January 2023
Verified
Conference Paper
Open access
JAJoão Pedro de Matos Assunção
João Pedro de Matos Assunção
GRGUSTAVO Gomes RESENDE
GUSTAVO Gomes RESENDE
AKAdriana Maria Kakehasi
Adriana Maria Kakehasi
SRSandra Lúcia Euzébio Ribeiro
Sandra Lúcia Euzébio Ribeiro
JSJuliana Alves Scrignoli
Juliana Alves Scrignoli
GFGilda Aparecida Ferreira
Gilda Aparecida Ferreira

30 January 2026 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
PPPaulo Chicarone Pereira
Paulo Chicarone Pereira
MYMichel Alexandre Yazbek
Michel Alexandre Yazbek
RMRafaela Bicalho Viana Macedo
Rafaela Bicalho Viana Macedo
FMFabiana Miranda Moura
Fabiana Miranda Moura
ABAntonio Luiz Boechat
Antonio Luiz Boechat
VAValderilio Azevedo
Valderilio Azevedo
Background: The increasing availability of biosimilars has raised important questions regarding their interchangeability with originator biologics in the treatment of immune-mediated rheumatic diseases. Addressing this issue is critical to ensuring patient safety, therapeutic efficacy, and informed clinical decision-making. Objective: To present a position statement from the Biotechnology Committee of the Brazilian Society of Rheumatology on the interchangeability between originator and biosimilar biologic drugs in rheumatologic care. Methods: A task force of 22 rheumatologists with expertise in immunobiological therapies followed a structured three-phase consensus process: (1) development of five key questions on biosimilar interchangeability; (2) comprehensive literature review using MEDLINE, EMBASE, and LILACS databases; and (3) final review and endorsement by relevant BSR committees. Expert opinion was used when evidence was limited or inconclusive. Results: The position statement comprises five consensus-based recommendations, all unanimously supported by the task force, and supported by current scientific evidence and clinical experience. Conclusion: The Biotechnology Committee of the Brazilian Society of Rheumatology endorses the safe and effective interchangeability of originator and biosimilar biologics when guided by principles that ensure patient safety, therapeutic continuity, and healthcare system sustainability. Clinical trial number: Not applicable.